The DOI matches its Crossref record; 228 of the 230 references it cites were found in a registry or an index.
Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes
Open accessAbstract
Post-transplant diabetes mellitus (PTDM) is a frequent consequence of solid organ transplantation. PTDM has been associated with greater mortality and increased infections in different transplant groups using different diagnostic criteria. An international consensus panel recommended a consistent set of guidelines in 2003 based on American Diabetes Association glucose criteria but did not exclude the immediate post-transplant hospitalization when many patients receive large doses of corticosteroids. Greater glucose monitoring during all hospitalizations has revealed significant glucose intolerance in the majority of recipients immediately after transplant. As a result, the international consensus panel reviewed its earlier guidelines and recommended delaying screening and diagnosis of PTDM until the recipient is on stable doses of immunosuppression after discharge from initial transplant hospitalization. The group cautioned that whereas hemoglobin A1C has been adopted as a diagnostic criterion by many, it is not reliable as the sole diabetes screening method during the first year after transplant. Risk factors for PTDM include many of the immunosuppressant medications themselves as well as those for type 2 diabetes. The provider managing diabetes and associated dyslipidemia and hypertension after transplant must be careful of the greater risk for drug-drug interactions and infections with immunosuppressant medications. Treatment goals and therapies must consider the greater risk for fluctuating and reduced kidney function, which can cause hypoglycemia. Research is actively focused on strategies to prevent PTDM, but until strategies are found, it is imperative that immunosuppression regimens are chosen based on their evidence to prolong graft survival, not to avoid PTDM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its unquestionable impact as a signi fi cant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [137]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical importance of PTDM lies in its impact as a significant risk factor for cardiovascular disease and chronic kidney disease in solid-organ transplantation (137).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,359
Cited by
Items 201–300 of 328
Lewinter, C., Widman, L., Melin, M., Wester, A., Shang, Y., & Hagström, H. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102172 · Cited by 2
Corrêa, L. M. D. A., Mazur, G. R., Santiago, C. B. G., Dante, L. E., Marco, P. S., & Ferrés, P. B. S. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101003 · Cited by 2
Langsford, D., Steinberg, A. G., & Dwyer, K. M. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0478-2 · Cited by 2
Lim, J., Hwang, I., Cho, J., Kwon, E., Jung, H., Choi, J., Park, S.-H., Kim, Y.-L., Kim, H.-K., Huh, S., et al. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.04.081 · Cited by 2
Missikpode, C., Durazo-Arvizú, R., Cooper, R., O’Brien, M. J., Castañeda, S. F., Talavera, G. A., Gallo, L. C., Llabre, M. M., Perera, M. J., Perreira, K. M., et al. (2021) · Journal of Diabetes · doi:10.1111/1753-0407.13224 · Cited by 2
“In addition, studies have reported higher risk for incident DM after coronary artery bypass graft surgery or transplant.(10,11) Furthermore, the physical impairment associated with CVD may limit the capacity of people with CVD to engage in physical activity(12) and promote weight gain,(13) which are both associated wi…”
BackgroundInterdisciplinary problem of post-transplant diabetes mellitus: literature review
Владимировна, Б. А., Mustafina, V. R., & Glinkina, I. V. (2021) · Sechenov Medical Journal · doi:10.47093/2218-7332.2021.12.1.60-73 · Cited by 3
Odler, B., Huemer, M., Schwaiger, E., Borenich, A., Kurnikowski, A., Krall, M., Hafner-Gießauf, H., Eleftheriadis, G. K., Bachmann, F., Faura, A., et al. (2023) · Transplant International · doi:10.3389/ti.2023.11370 · Cited by 3
Dong, Y. (2023) · Investigación Clínica · doi:10.54817/ic.v64n4a03 · Cited by 2
Ha, K. L., Văn, Đ. N., Manh, H. D., Thi, D. T., Trung, K. N., Viet, T. L., & Thu, H. N. T. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s490561 · Cited by 3
Caturano, A., Martino, A. D., Albanese, G., Coppola, C., Russo, V., Koudelková, K., Galiero, R., Rinaldi, L., Sardu, C., Marrone, A., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02406-x · Cited by 3
“Acknowledging the sensitivity of the immediate postoperative period for liver transplant recipients, the initiation of weight loss initiatives must be approached judiciously to avoid potential adverse impacts on the trajectory of post-surgical recovery [26].”
Association of COVID-19 With Risk of Posttransplant Diabetes Mellitus
Vinson, A. J., Anzalone, A. J., Schissel, M. E., Dai, R., Olex, A. L., Mannon, R. B., & Collaborative, O. B. O. T. N. C. C. (2024) · Transplantation · doi:10.1097/tp.0000000000005227 · Cited by 2
“23 Given the known consequences of PTDM, including increased healthcare utilization and expenditure, graft compromise, premature cardiovascular events, and mortality, 24 the identification of risk factors for PTDM is imperative.”
Posttransplant Diabetes Mellitus after Liver Transplantation: Risk Factors for Persistence
Kang, B. J., Park, H. W., & Nah, Y. W. (2016) · Korean Journal of Transplantation · doi:10.4285/jkstn.2016.30.3.125 · Cited by 2
“반면에 PTDM은 수술 후 수년 이상 경과한 이후에도 발생할 수 있는바(16), 본 연구에서도 두 명의 환자가 수술 후 6개월 이후에 발병 하였다.”
Pre, peri and posttransplant diabetes mellitus
Essawy, B. E., & KANDEEL, F. R. (2018) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000469 · Cited by 3
Kharazmkia, A., Ziaie, S., Ahmadpoor, P., Moradi, O., Khoshdel, A., Pour-Reza-Gholi, F., Samavat, S., Samadian, F., & Nafar, M. (2020) · Shiraz E-Medical Journal · doi:10.5812/semj.98656 · Cited by 2
“As declared in previous studies, Pioglitazone is an effective agent for the treatment of diabetes in this population, as evidenced by improvement in HgbA1c levels (34-36).”
MethodArabi, Z., Elhassan, E., Abdalla, M. I., Farooqui, M. A., Mateen, A., Kaysi, S., Alam, S., Khan, S., El-Muzaini, M. F., Sabbagh, M. A., et al. (2020) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.301202 · Cited by 2
Khan, S. F., & Bowman, B. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-54945-5.00012-6 · Cited by 2
Pieloch, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-44858-5_18 · Cited by 2
Petrosan, A., Santeusanio, A. D., Khaim, R., & Delaney, V. B. (2022) · Progress in Transplantation · doi:10.1177/15269248221122869 · Cited by 2
“These mechanisms, in combination with patient specific risk factors such as increased age and obesity, result in an overall prevalence of diabetes as high as 74% in kidney transplant patients.(2,3) Potential treatment options for DMposttransplant include both insulin as well as various oral agents.”
BackgroundTanni, K. A., & Qian, J. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.02.006 · Cited by 2
Tomioka, Y., Sugimoto, S., Shiotani, T., Matsubara, K., Choshi, H., Ishihara, M., Tanaka, S., Miyoshi, K., Otani, S., & Toyooka, S. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.01.001 · Cited by 2
Prediction of Early Kidney Transplant Graft Outcome: Insulin Resistance Index
Lin, T.-C., Lin, K.-J., Chiang, Y., Chu, S., Liu, K., Lin, C.-T., Pan, P., Chen, S.-Y., Wang, J.-C., & Wang, H.-H. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.01.033 · Cited by 2
Food, Nutrition and Hydration Policy For Adult Patients in Acute Hospitals
Quality, H., & Lead, A. O. S. (2018) · Cited by 4
New-Onset Diabetes After Heart Transplantation: A Call to Arms
Epailly, E. (2021) · Transplantation · doi:10.1097/tp.0000000000003648 · Cited by 1
“A recent large review concluded that posttransplant diabetes mellitus does not affect survival based on a few retrospective studies with small cohorts.(2)”
BackgroundVigara, L. A., Villanego, F., Orellana, C., Eady, M., Sánchez, M. G., Alonso, M., García, M. B., Amaro, J. M., García, T. G., & Mazuecos, A. (2023) · Nefrología · doi:10.1016/j.nefro.2023.06.010 · Cited by 2
Potential Mechanism Associated with Post–Heart Transplantation Diabetes Mellitus in Chinese Patients
Huang, X., Xu, Q., Chen, L., Liu, L., Zhou, Y., Zhou, H., & Zhang, Y. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf071 · Cited by 1
Tai, C., Huang, K., Wang, J., Gau, S., Huang, S.-W., Su, K.-Y., Tsai, T., Wu, C.-N., & Lee, C. (2025) · Healthcare · doi:10.3390/healthcare13050523 · Cited by 2
“Risk factors for PTDM, including insulin resistance, hypertension, hyper-triglyceridemia, and obesity, are similar to those for T2DM, but PTDM is influenced by specific predisposing posttransplant factors [36].”
Malyala, R., Vansjalia, K., Nash, M. M., Dacouris, N., Rapi, L., & Prasad, G. V. R. (2025) · Kidney360 · doi:10.34067/kid.0000000763 · Cited by 1
“12,14 Since the International Consensus Guidelines in 2003, signi fi cant advances in diabetes mellitus (DM) management in the general population have prompted the third international PTDM Consensus Meeting in 2024.”
Use of Semaglutide in Diabetes Care Post Renal Transplantation
Alluhayyan, O. B., Almutawa, F., Alghamdi, Y. I., Alyousef, K., Altaleb, K. A., Alghamdi, H., & Mahzari, M. M. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00463-x · Cited by 1
“Concerns about the safety and tolerability of GLP-1 RAs in kidney transplant patients focus on potential gastrointestinal side effects, which could affect the absorption of immunosuppressive drugs [26].”
Nutritional management of kidney transplant recipient
Sengupta, P., Chaudhuri, A., Rathore, K., & Biswas, S. (2025) · Proceedings of Singapore Healthcare · doi:10.1177/20101058251327810 · Cited by 1
“9,10 Planning nutritional therapy for transplant recipients should therefore consider the patient ’ s clinical condition, comorbidities, and nutritional needs at each stage of the transplant process, as depicted in Figure 1, which outlines these phases and complications.”
Dolinar, K., Miš, K., Šopar, K., Šutar, M., Božič, M., Kolar, M., Hropot, T., García-Rovés, P. M., Chibalin, A., & Pirkmajer, S. (2025) · BioFactors · doi:10.1002/biof.70037 · Cited by 2
“…of purine metabolism, which are often used to treat inflammatory diseases and other conditions associated with glucose dysregulation [8, 12–16], could provide additional therapeutic benefit, especially over those immunosuppressants and antineoplastics that increase the risk of diabetes [17, 18].”
Gardiner, C., Keane, D. F., Ho, E. C. L., Lenfant, V., Tankisi, O., Yam, M. H. C., & Daga, S. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04419-2 · Cited by 1
“It is well documented that PTDM has a greater metabolic burden; therefore, an impact on transplant outcomes is plausible [50].”
Total Joint Arthroplasty in Solid Organ Transplant Patients
Khury, F., Ruff, G. L., Sarfraz, A., & Schwarzkopf, R. M. (2025) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2025.08.002 · Cited by 1
Navarrete, R. E. T., Freitas, J. C., Fonseca, I. M., Cunha, A., de Sá, J. R., & Martins, L. S. (2025) · Diabetology · doi:10.3390/diabetology6120158 · Cited by 1
Non-traditional cardiovascular risk factors after kidney transplantation
Belal, A. A., Santos, A. H., Jr., & Kazory, A. (2025) · World Journal of Nephrology · doi:10.5527/wjn.v14.i4.110896 · Cited by 1
Etayo-Urtasun, P., de Asteasu, M. L. S., & Izquierdo, M. (2026) · Transplantation Reviews · doi:10.1016/j.trre.2026.101001 · Cited by 1
Chen, N., Chen, Y., Liu, Q., & Shu, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1838424 · Cited by 2
He, Y., Luo, C., He, S., Li, S. B., Zhou, H., & Wei, S. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05739-2 · Cited by 1
“…use, including nephrotoxicity (Naesens et al. 2009; Nankivell et al. 2016), neurotoxicity (Senzolo et al. 2009), new-onset diabetes after transplantation (NODAT) (Shivaswamy et al. 2016), hypertension (Hoorn et al. 2011), and increased risks of infection and malignancy (Dantal and Soulillou 2005).”
Evidence-Based Cardiovascular–Kidney–Metabolic Therapies in Kidney Transplant Recipients
Shroff, G. R., Cheng, X. S., Gharabagi, A., Lin, C.-J., Benjamin, M. M., & Lentine, K. L. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001195 · Cited by 1
Administration of metformin in renal transplant patients with post-transplant diabetes mellitus
Asgharpour, M., Mirhashemi, S. H., & Alirezaei, A. (2019) · Journal of Renal Injury Prevention · doi:10.15171/jrip.2019.35 · Cited by 1
“These withdrawal recommendations are likely to be indicated at early post transplant phase because of higher risk of metformin complications at this time period (17,18).”
BackgroundDiagnosis of acute intermittent porphyria in a renal transplant patient: A case report
Sirch, C., Khanna, N., Frassetto, L. A., Bianco, F., & Artero, M. L. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i1.8 · Cited by 1
Renal Allograft Survival: Incidence and Risk Factors Associated with Graft Dysfunction
Alalawi, F. J. A., Gulzar, K., Seddik, A. A., Alnour, H. H., Ahmad, M., Najad, S., Osman, O. E., Yousif, H., Railey, M., & Alhadari, A. K. (2023) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_93_22 · Cited by 1
Fu, J., Zhang, Q., Zhang, N., Zhou, S., Fang, Y., Li, Y., Li, Y., Chen, L., & Xiang, C. C. (2024) · Biomolecules · doi:10.3390/biom14060671 · Cited by 1
“However, islet transplantation still faces related problems, and post-transplant diabetes mellitus is one of the most prevalent complications, which is closely linked to the use of immunosuppressants [4].”
BackgroundEvaluation of transplant pharmacist‐led post‐transplant hyperglycemia service
Ho, K., Cohen, E., Do, V., Girone, G., Marvin, J. E., & Belfield, K. D. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.2073 · Cited by 1
“9 As a result, the timing of PTDM diagnosis has been debated.”
Mačáková, D., Zadražil, J., Karásek, D., Kučerová, V., Langová, K., & Cibičková, Ľ. (2025) · BMC Nephrology · doi:10.1186/s12882-024-03938-8 · Cited by 1
“The diabetogenic effect of glucocorticoids is dose-dependent, with induction protocols having a greater diabetogenic potential than long-term maintenance doses [29, 30].”
Liarakos, A. L., Panagiotou, G., Chondronikola, M., & Wilmot, E. G. (2025) · Life · doi:10.3390/life15101579 · Cited by 6
“People receiving solid organ transplantation have a high risk of developing diabetes mellitus, known as post-transplant diabetes mellitus (PTDM) [13].”
New Onset Diabetes After Transplant (NODAT)
Solhjoo, M., & Kumar, S. C. (2019) · StatPearls · Cited by 1
Diabetes in Kidney Transplant Recipients
Dhital, S. M. (2018) · Springer eBooks · doi:10.1007/978-3-030-00132-2_10 · Cited by 1
Infante, M., Padilla, N., Madiraju, S. K., Alvarez, A., Baidal, D. A., Ricordi, C., & Alejandro, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814833-4.00037-x · Cited by 1
Manni, A., & Quarde, A. (2020) · Springer eBooks · doi:10.1007/978-3-030-49872-6_4 · Cited by 1
Liew, Z. H., Tan, P. H., Foo, M., Kee, T. Y. S., & Ho, Q. Y. (2021) · CEN Case Reports · doi:10.1007/s13730-020-00546-x · Cited by 1
“AGE Advanced glycation end product CKD Chronic kidney disease CNI Calcineurin inhibitors DM Diabetes mellitus DN Diabetic nephropathy EM Electron microscopy HbA1c Glycated hemoglobin HLA Human leukocyte antigen KTR Kidney transplant recipient IFG Impaired fasting glucose IGT Impaired glucose tolerance IMF Immunofluore…”
BackgroundInfluentialAnesthetic Concerns in Endocrine Cancers
Subramaniam, R. (2021) · Springer eBooks · doi:10.1007/978-981-16-0006-7_17 · Cited by 1
Post-liver transplantation diabetes mellitus — a clinical challenge for diabetologists?
Bhadada, S. K., & Pal, R. (2021) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-021-00955-3 · Cited by 1
“The International Consensus Guidelines on new-onset diabetes after transplantation 2003 recommended that the diagnosis should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes mellitus [6], which are as follows: & Fasting plasma glucose (FPG) ≥ 7.0 mmol/l (126 mg/dl) with no calorie inta…”
BackgroundInfluentialImmunosuppressive agents and monitoring in long‐term survivors
Culos, K. A. A., & Gatwood, K. S. (2021) · Wiley eBooks · doi:10.1002/9781119612780.ch37 · Cited by 1
Medical Complications After Kidney Transplantation: Early
Brahmbhatt, Y. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-14779-6_14-1
Tacrolimus-associated diabetic ketoacidosis: a case report and literature review
Pak, S., Hirschbeck, M., Valencia, D. N., Valencia, V., Askaroglu, Y., Nye, D., & Fershko, A. (2018) · Southwest Journal of Pulmonary and Critical Care · doi:10.13175/swjpcc015-18
“The reduction in survival rate due to post-transplant diabetes mellitus is largely due to cardiovascular disease, such as coronary artery disease and congestive heart failure (9).”
BackgroundTHE INDIVIDUAL TAILORING OF IMMUNOSUPPRESSIVE THERAPY AFTER HEART TRANSPLANTATION
Николаевна, К. Н., Попцов, В. Н., & Шевченко, А. О. (2018) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2018-1-127-137
Functional in vitro studies of immunosuppressive agents in human pancreatic islets
Kloster‐Jensen, K. (2018) · NORA - Norwegian Open Research Archives
Alvarez, A. M., Pompey, N. A. L., Ochoa, O. A. V., Lenis, G., Corrales, M., Cala, H., Guerra, A., Toro, L., Correa, E., Tavera, L. F. C., et al. (2018) · Revista Colombiana de Gastroenterología · doi:10.22516/25007440.190
The Conundrum of High Body Mass Index in Kidney Transplant Patients
Bellini, M. I., Ayathamattam, J., & Herbert, P. E. (2018) · OBM Transplantation · doi:10.21926/obm.transplant.1804026
“As obesity is associated with an increased risk of steroid induced diabetes and CVD risk factors [28], our centre policy is to withdraw them early, within the first week post-transplant [12].”
BackgroundDiabetes Mellitus Pós-transplante (DMPT)
Pinheiro, I. D. O., Gadelha, D. D., de Carvalho, M. M. D., de Queiroz, P. C., Fernandes, V. O., & Montenegro, R. M. (2019) · Revista de Medicina da UFC · doi:10.20513/2447-6595.2019v59n1p77-78
Management of new onset diabetes after transplantation (NODAT) with use of novel algorithm
Lakhani, O. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00741-2
“Regular assessment for microvascular and macrovascular complications of diabetes mellitus must be performed in patients with NODAT [10].”
BackgroundImmunosuppressive Drugs and Kidney Post-transplant Diabetes Mellitus
Bilal, I., & Azeez, S. H. (2019) · Hospital Practices and Research · doi:10.15171/hpr.2019.09
Arabi, Z., Ghalib, B., Asmari, I., Gafar, M., Alam, S. A., Abdulgadir, M. Y., Alshareef, A., Rashidi, A., Alruwaymi, M., & Altheaby, A. (2020) · Avicenna Journal of Medicine · doi:10.4103/ajm.ajm_120_19
“- Delivery in transplanted patient can be through vaginal route if there is no indication for cesarian section.[1,54-68] 16.”
Background¿Los protocolos experimentales son un símil real de la diabetes humana?
Moreno-Cortés, M. L., Gutiérrez‐García, A. G., & Contreras, C. M. (2020) · CienciaUAT · doi:10.29059/cienciauat.v14i2.1289
Друк, И. В., Дрокина, О. В., Lyalyukova, E. A., Ряполова, Е. А., Vysokogorskiy, V. E., & Moliboga, E. A. (2018) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-156-8-107-115
Alteraciones del metabolismo de la glucosa en donante y receptor
Martínez-Juárez, I. A. (2020) · Revista Mexicana de Trasplantes · doi:10.35366/93494
Patient after kidney transplantation in outpatient internal clinic
Roháľ, T. (2020) · Vnitřní lékařství · doi:10.36290/vnl.2020.075
Effect of Diallyl Disulphide on Hepatic Glucose Regulating Enzymes in Diabetic Rats
(2020) · Indian Journal of Biochemistry and Biophysics · doi:10.56042/ijbb.v57i5.26847
Frecuencia de hipertensión arterial, diabetes y dislipidemia en niños con trasplante renal
Serna-Higuita, L. M. (2021) · Revista M�dica del Instituto Mexicano del Seguro Social · doi:10.24875/rmimss.m20000009
Mrzljak, A., Jelić, A., Franušić, L., Likić, R., & Adžić, Z. O. (2020) · Liječnički vjesnik · doi:10.26800/lv-142-7-8-34
Suhecka, K., Lejnieks, A., Jushinskis, J., Maļcevs, A., Suhorukovs, V., Amerika, D., Straupmane, D., Pētersons, A., & Ziediņa, I. (2021) · Proceedings of the Latvian Academy of Sciences Section B Natural Exact and Applied Sciences · doi:10.2478/prolas-2021-0016
PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS- CURRENT KNOWLEDGE AND RECENT ADVANCES: MINI REVIEW
Sinha, A., Loganathan, S., Krishnan, S., Mahanta, A., G., N. P., & Bhattacharjee, M. (2021) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/5003168
Cadaveric kidney allotransplantation at Krasnoyarsk Regional Clinical Hospital
Arutiunian, V. S. A., Keosyan, A. V., Анатольевич, Ф. М., Evdokimov, D. P., Tsokaev, M. R., Amelchugova, O. S., & Лукичева, Э. В. (2021) · Russian Journal of Transplantology and Artificial Organs · doi:10.15825/1995-1191-2021-2-41-51
Diabète post-transplantation rénale: le point de vue du diabétologue
Pauchet, A., Schwotzer, N., Lamine, F., Perrottet, N., Zanchi, A., Golshayan, D., & Wojtusciszyn, A. (2020) · JMIG · doi:10.53738/revmed.2020.16.697.1200
Struja, T., Nitritz, N., Alexander, I., Kupferschmid, K., Hafner, J. F., Spagnuolo, C., Schüetz, P., Müeller, B., & Blum, C. A. (2022) · Research Square · doi:10.21203/rs.3.rs-2194086/v1
Petkovska, L., Simonovska, N., Babulovska, A., Berat-Huseini, A., Kavrakova, J. B., Petronijevik, Z., & Ivanovska, B. Z. (2022) · Journal of Morphological Sciences · doi:10.55302/jms2253035p
Okumi, M., Omoto, K., Shimizu, T., Shirakawa, H., Unagami, K., Lee, T., Ishida, H., Tanabe, K., & Takagi, T. (2023) · International Journal of Urology · doi:10.1111/iju.15163
Not so sweet!!: Posttransplant diabetes ‒ An update for the nephrologist
Jose, N., & Varughese, S. (2023) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_97_22
Kumar, D., Gulzar, K., Alalawi, F. J. A., Seddik, A. A., Alnour, H. H., Ahmed, M., Najad, S., Yousif, H., Railey, M., & Alhadari, A. K. (2023) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000531665
Kotwal, N., Bansal, N., Muthukrishnan, J., & Verma, V. (2023) · Medical Journal Armed Forces India · doi:10.1016/j.mjafi.2023.08.017
Formulas for Successful Pancreas Transplant Programs
Carpenter, J., & Abrams, P. L. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_76
The Medical Challenge of Lung Transplantation
Vitulo, P., Martino, L., Callari, A., & Lanzarone, N. (2023) · Organ and tissue transplantation · doi:10.1007/978-3-319-20788-9_2-1
Induction immunosuppression and post-transplant diabetes mellitus: a propensity-matched cohort study
Gupta, S., Mostofsky, E., Motiwala, S. R., Hage, A., & Mittleman, M. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1248940 · Cited by 2
Omics reveal the difference between PTDM and T2D among the liver, pancreas and adipose tissuePreprint
Liu, Y., Wen, P., Yang, Y., He, Q., Shi, W., Xia, Y., Wang, H., Tang, Y., Wang, R., Zhang, T., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3560838/v1
Diabetes mellitus pós-transplante renal: relato de caso
Samara, S. C., Bartolomeo, F. F., Neto, P. F. A., Gyotoku, L. C., & Batista, S. L. (2024) · Revista Interdisciplinar de Saúde e Educação · doi:10.56344/2675-4827.v4n2a2023.17
Immunity Risk Associated With Cytomegalovirus Infection After Organ Transplantation
Roy, S., Ghosh, S., Karmakar, S., Sarkar, S., Sarkar, S., & Ghosh, B. (2023) · Journal Of Advanced Zoology · doi:10.53555/jaz.v44is5.3202
Hyperglycemia and Diabetes in the Posttransplant Patient
Dowlatshahi, S., Zahid, M., & Sadhu, A. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_20
The Medical Challenge of Lung Transplantation
Vitulo, P., Martino, L., Callari, A., & Lanzarone, N. (2024) · Organ and tissue transplantation · doi:10.1007/978-3-030-36123-5_2
Tacrolimus Therapeutic Response, Pharmacokinetics and Adherence in Liver Transplant Recipients
Daldoul, M., Charfi, R., Ferchichi, K., Sassi, M. B., Hammamia, S. B., Medhioub, F., Gaïes, E., Rym, E., Eljebari, H., Klouz, A., et al. (2024) · OBM Transplantation · doi:10.21926/obm.transplant.2404228
“Tacrolimus seemed to be associated with a greater risk of induced diabetes mellitus than cyclosporine after liver transplantation [59, 61].”
Current strategies in managing metabolic complications following liver transplantation
Lee, S. K. (2025) · Annals of Liver Transplantation · doi:10.52604/alt.24.0025
Tacrolimus and diabetic rodent models
Qian, M., Guan, M., Wang, L., & Hu, N. (2025) · Pharmacological Reports · doi:10.1007/s43440-024-00693-3
“Among the adverse reactions of TAC—including glucose metabolism disorders, nephrotoxicity, and increased risk of infection and malignant tumors [11]—post-transplantation diabetes (PTDM) represents a major complication [12].”
Fei, L., Wang, H., Zhao, D., Wang, X., Ren, J., Liu, L., Tang, C., Yan, L., Wang, Q., Nie, Y., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01282-7
“For patients with irreversible end-stage organ failure, solid organ transplantation (SOT) is the optimal therapeutic option (Jenssen and Hartmann 2019; Larsen et al. 2016).”
Distinguiendo lo indistinguible: nefropatía diabética en no diabéticos
Gonzalez, G. T. F., Almeida-Borjon, O., Carmona-Escamilla, M. A., Abraham, V. S., Cano-Cervantes, H., Matías-Carmona, M., & Canade-Hernández, R. (2025) · Revista Mexicana de Trasplantes · doi:10.35366/120822
Motohashi, K., Murakami, T., Otani, D., Nakamura, T., Kato, T., Seguchi, O., Ogura, M., Yabe, D., & Inagaki, N. (2025) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-25-0038
de Souza, T. C. S., Brasil, I. R. C., de Sandes‐Freitas, T. V., Gouveia, E. B. C., Rabelo, F. C. S., & Dallago, C. M. (2025) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v28i1.706_eng
de Souza, T. C. S., Brasil, I. R. C., de Sandes‐Freitas, T. V., Gouveia, E. B. C., Rabelo, F. C. S., & Dallago, C. M. (2025) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v28i1.706_port
Primary Care of the Adult Liver Transplant Recipient
Tuegel, C., Beste, L. A., & Larson, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-98076-3_5
Metadata
- Authors
- Shivaswamy, V., Boerner, B., & Larsen, J.
- Affiliations
- VA Nebraska Western Iowa Health Care System (US)
- University of Nebraska Medical Center (US)
- Corresponding author
- Larsen, Jennifer
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2015-12-09
- Volume
- 37
- Issue
- 1
- Pages
- 37-61
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC4740345
- OpenAlex
- W2190934800
- Cited by
- 328
- References
- 230
- Citations by year
- 2026: 30 · 2025: 36 · 2024: 35 · 2023: 31 · 2022: 32 · 2021: 44 · 2020: 51 · 2019: 29 · 2018: 30 · 2017: 5 · 2016: 4
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Office of Research and Development
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- post-transplant diabetes mellitus, solid organ transplantation, immunosuppression, corticosteroids, impaired glucose tolerance, diabetes screening, HbA1c, type 2 diabetes risk factors, drug-drug interactions, hypoglycemia, graft survival, mortality, infection risk, diabetes treatment
- MeSH terms
- Adrenal Cortex Hormones, Animals, Combined Modality Therapy, Diabetes Mellitus, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Postoperative Complications, Risk Factors, Stress, Physiological, Organ Transplantation, Cost of Illness, Practice Guidelines as Topic, Evidence-Based Medicine, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.